The size of the Liver Disease Treatment Market in the European region is expected to reach USD 4.01 billion by 2027 from USD 2.32 billion in 2022, growing at a CAGR of 11.56% during the forecast period.
The percentage of the aged population diagnosing with liver-related diseases is significantly increasing in Europe and is primarily driving the growth of the European liver disease treatment market. Europe is among one of the leading markets for Liver Disease Treatment Drugs. As per a report, liver cirrhosis causes 170,000 deaths in Europe annually. Within Europe, Germany, France, and the United Kingdom account for the largest liver disease treatment market share.
Various technological advancements in the imaging techniques, Y-O-Y increase in the patients diagnosing with the liver diseases further contribute to the growth of the market. The increasing number of mergers and acquisitions that are happening between the companies is predicted to shape the face of the market better during the forecast period. The license expiration of a few drugs and robust pipeline drugs for the treatment of liver diseases is adding fuel to the market.
Strict regulations of the FDA, MHRA in approving the new drugs, and high costs required for the development of new drugs, and the high costs associated with the treatment for liver diseases are expected to hamper the market growth to a specific limit.
This research report on the Europe Liver Disease Treatment Market has been segmented and sub-segmented into the following categories:
By Treatment Modality:
By Disease Type:
By Country:
Regional Analysis:
Geographically, the European liver disease treatment market stands second, following North America in leading the global liver disease treatment market. It is due to viral hepatitis, genetic disorders, unhealthy diet, and excessive intake of alcohol.
Germany, UK, and France account for significant shares of the liver disease treatment market in the region. The growing number of liver disease cases because of the vast drinking population in Europe and increasing obesity and growing new clinical needs in liver diseases are likely to accelerate market growth. The Germany market is rising due to factors like excess intake of over-the-counter high dosage drugs, reimbursement policies for liver diseases in the healthcare sector, government, and other private organizations bring out the awareness by organizing programs regarding liver disease treatment which propels the market during the analysis period. Alcohol consumption is considered to cause 20%-50%of cirrhosis of the liver, and around 13% of the population across the globe, i.e., more than 600 million adults, are obese according to World Health Organization. Moreover, Cirrhosis can cause 170,000 deaths in Europe every year.
Companies playing a vital role in the European Liver Disease Treatment Market profiled in the report are Gilead Science Inc. (U.S.), Pfizer Inc. (U.S.), Merck & Co. (U.S.), Johnson & Johnson (U.S.), Novartis (Switzerland), Roche (Switzerland), Sanofi-Aventis (France), Abbott Laboratories (U.S.), Bayer Schering AG (Germany) and AstraZeneca (United Kingdom).
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5.1 Treatment Modality
5.1.1 Introduction
5.1.2 Antiviral
5.1.3 Vaccines
5.1.4 Chemotherapy
5.1.5 Immunosuppressive Agents
5.1.6 Corticosteroids
5.1.7 Others
5.1.8 Y-o-Y Growth Analysis, By Product
5.1.9 Market Attractiveness Analysis, By Product
5.1.10 Market Share Analysis, By Product
5.2 Disease Type
5.2.1 Introduction
5.2.2 Hepatitis
5.2.3 Non-Alcoholic Fatty Liver Disease
5.2.4 Alcohol Induced
5.2.5 Liver Cancer
5.2.6 Others
5.2.7 Y-o-Y Growth Analysis, By Type
5.2.8 Market Attractiveness Analysis, By Type
5.2.9 Market Share Analysis, By Type
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Product
6.1.3.3 By Type
6.1.3.4 By Application
6.1.3.5 By Indication
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Product
6.1.4.3 By Type
6.1.4.4 By Application
6.1.4.5 By Indication
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Product
6.1.5.3 By Type
6.1.5.4 By Application
6.1.5.5 By Indication
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Gilead Science Inc
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Pfizer Inc.
8.3 Merck & Co.
8.4 Johnson & Johnson
8.5 Novartis
8.6 Roche
8.7 Sanofi-Aventis
8.8 Abbott Laboratories
8.9 Bayer Schering AG
8.10 AstraZeneca
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
Related Reports
Talk to our analyst and get customised report done according to your research needs
Check if you can avail any discount. Submit your details and our team will get back to you.
Request to avail a free sample report that reflects this market and its growth.